• GENE THERAPY

Development of gene therapy products has been accelarating as a new modality for the treatment of traditionally challenging diseases. Synplogen is building the capacity for DNA synthesis as well as viral vector production and characterization all under one roof, quickly and effectively meeting your viral vector needs.

Capabilities

DNA Construction

DNA makes up the genes which function as blueprints for gene therapy treatments, determining effectiveness, safety, productivity and quality. Synplogen's proprietary DNA synthesis techniques allow for the construction of traditionally challening gene sequences, and is leveraged for the creation of particularly desirable plasmid DNA for viral vectors.

DNA Construction

Plasmid DNA Preparation

Creation of viral vectors for gene therapy applications requires significant volumes of plasmid DNA. Synplogen is developing microbial cultivation processes that result in high plasmid DNA yield, ensuring you always have enough plasmid DNA on hand.

Plasmid DNA Preparation

Viral Vector Preparation

Viral vectors are generated through DNA transfection. Synplogen is developing cell culture processes that result in sufficiently high titers for pharmacological and safety studies.

Viral Vector Preparation

Vector Characterization

Proper characterization of viral vectors is a critical step in a gene therapy development lifecycle. Synplogen utilizes cutting edge analysis equipment to provide you with the characterizations necessary to push your development project forward.

Vector Characterization

Flow

Select "Gene therapy vector preparation/characterization" from the contact form and submit your request details.

Select "Gene therapy vector preparation⁄characterization" from the contact form and submit your request details.

You will be contacted shortly by a Synplogen representative. Please also provide information regarding the nucleic acid and vector.
(An NDA/CDA can be signed if necessary.)

You will be contacted shortly by a Synplogen representative. Please also provide information regarding the nucleic acid and vector.

Synplogen's technical staff and safety committee will determine whether your request can be accepted.

Synplogen's technical staff and safety committee will determine whether your request can be accepted.

If your request can be accepted, you will be provided with an estimate for the services. After receiving confirmation of your order, the requested work will begin.

If your request can be accepted, you will be provided with an estimate for the services. After receiving confirmation of your order, the requested work will begin.

*For joint R&D inquiries and technical questions,
please use the same contact form.

Disclaimers

  • Viral vectors provided by Synplogen may only be used for research and may not be used for clinical or diagnostic applications. If the provided samples are used for anything other than research, Synplogen accepts no liability for any loss or damage that may arise from such use.
  • If viral vectors are necessary for commercial use, please make this clear in your inquiry. A licensing agreement may be necessary.
  • Follow all direction and guidelines for treatment and handling of viral vectors which are provided by law, ordinance (laws governing use of GMOs/LMOs for the protection of biodiversity, local regulations for the appropriate biosafety level/containment measures, etc.) or safety authority (government body or affiliated organization).